Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic
  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

New Model N Executive Report Places Technology as Central to Solving Revenue Management Issues in 2022

“2022 State Of Revenue Report” Shows Revenue Management Remains Susceptible to Changing Business Dynamics, Including Supply Chain, AI and Staffing Issues

Model N, Inc. (NYSE: MODN), a leader in cloud revenue management solutions, today announced the results of its fourth annual State of Revenue Report, A Survey of Top Industry Executives. Overall, 99% of executives report revenue management challenges within their own companies, and a large majority (85%) of executives surveyed agree that revenue management – which incorporates the ongoing optimization of revenue activities, including rebates, compliance, contracts, and pricing models to maximize growth – is “business critical.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322005276/en/

2022 State Of Revenue Report Shows Revenue Management Remains Susceptible to Changing Business Dynamics, Including Supply Chain, AI and Staffing Issues (Photo: Business Wire)

2022 State Of Revenue Report Shows Revenue Management Remains Susceptible to Changing Business Dynamics, Including Supply Chain, AI and Staffing Issues (Photo: Business Wire)

Across life sciences and high-tech companies, revenue management challenges continue to evolve. Survey respondents said that “top impacts” on revenue management include supply chain disruptions (44%) and artificial intelligence (40%), and 98% of executives say they face staffing issues in their revenue management program. Over half (51%) expect that issues with staffing and lack of available expertise will have a “significant” impact on revenue management in 2022.

How Executives Feel About the Pandemic

In a change from 2021, the COVID-19 pandemic was described as a critical revenue management challenge by 37% of executives, versus 58% the prior year. This sentiment can be attributed to other pressing issues in the market such as the prevalence of supply chain disruptions and staffing issues, which have become as pressing, if not more so, than the pandemic itself.

Using Revenue Management Technology

An overwhelming 99.7% of executives said “yes” when asked if additional technology capabilities would have specific benefits for their organizations. Looking deeper into what specific aspects of technology and solutions are needed, 80% of executives identified needing access to accurate and timely revenue management data.

“Our research illustrates that revenue management remains a challenge and that the revenue management function is still a top-priority for the C-suite,” said Suresh Kannan, Chief Product Officer at Model N. “The survey results also show that execs have an ingrained understanding that technology-based solutions – including the cloud, embedded AI and data analytics – are critical to tackling enterprise-wide revenue management issues and revenue leakage in 2022 and beyond.”

Model N’s Use of Research to Inform Product Innovation

Model N leverages proprietary research such as the 2022 State of Revenue Report to help inform ongoing product development and innovation—developing solutions that help answer ongoing market demands and needs.

An example of a recent demand-driven innovation from Model N is the new State Price Transparency Management solution, which ensures pharma companies are compliant with all state-level price transparency regulations.

Additionally, Expert Services, which is a part of Business Services from Model N help clients address critical staffing issues around revenue management by enhancing life sciences manufacturer teams with experts who specialize in government programs, commercial contracting, finance, and analytics.

Pharma and Medtech: Regulatory Compliance Takes a Leading Role

According to the report, regulatory compliance at state and federal levels is a concern for 81% of executives at life sciences organizations, which include both pharma and medtech companies. While compliance is an issue for business leaders at pharmaceutical (83%) and medtech (77%) companies, pharma executives are more concerned. Nearly two-thirds (60%) of pharmaceutical executives expect managing compliance to become even more difficult in 2022.

High Tech

In the high-tech sector, which includes semiconductor, electronic component manufacturers and high-tech manufacturing, leading concerns centered around managing and controlling data (34%), but also on maintaining financial compliance (30%) and managing global pricing (29%).

To get more industry-specific statistics and commentary about revenue management and the impact of channels and data for life sciences and high tech, download the full 2022 State of Revenue Report:

www.modeln.com/state-of-revenue-report-2022

More About the 2022 State of Revenue Report

On behalf of Model N, Dimensional Research polled 306 qualified executives with direct responsibility for revenue management at companies with more than $250 million in annual revenue. The research covered a range of topics, including current revenue management approaches, opportunities for improvement, and the role of technology in revenue management. To enable trend analysis, certain questions were repeated from studies conducted with a similar audience in 2020 and 2021.

About Model N

Model N enables life sciences and high-tech companies to drive growth and market share, minimizing revenue leakage throughout the revenue lifecycle. With deep industry expertise, solutions and business services purpose-built for these industries, Model N delivers comprehensive visibility, insight and control over the complexities of commercial operations and compliance. Our integrated cloud solution is proven to automate pricing, incentive and contract decisions to scale business profitably and grow revenue. Model N is trusted across more than 120 countries by the world’s leading pharmaceutical, medical technology, semiconductor, and high-tech companies, including Johnson & Johnson, AstraZeneca, Stryker, Seagate Technology, Broadcom, and Microchip Technology. For more information, visit www.modeln.com.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.